Ezetimibe
It is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion. Instead ezetimibe localized and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood, this distinct mechanism is complementary to that of HMG-CoA reductase inhibitors.Primary Hypercholesterolemia Monotherapy, Combination therapy with HMG-CoA reductase inhibitors, Homozygous Familial hypercholesterolemia (HoFH), Homozygous Sitosterolemia.
10mg once daily.
Hypersensitivity, Pregnant and nursing women.
Hepatic insufficiency, Carcinogenesis, mutagenesis, impairmenta of fertility, pregnancy, nursing mother.